Studies on the anticonvulsant activity and influence on GABA-ergic neurotransmission of 1,2,4-triazole-3-thione-based compounds

Molecules

Volumn 19, Issue 8, 2014, Pages 11279-11299

  Plech, Tomasz ^a   Kaproń, Barbara ^a   Łuszczki, Jarogniew J ^a,b   Wujec, Monika ^a   Paneth, Agata ^a   Siwek, Agata ^c   Kołaczkowski, Marcin ^c   Zołnierek, Maria ^c   Nowak, Gabriel ^c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

30 688 s triazoles; Blood brain barrier (BBB); Mannich bases; Maximal electroshock induced seizure (MES) test; Radioligand binding assay

Indexed keywords

ANTICONVULSIVE AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; TRIAZOLE DERIVATIVE;

ANIMAL; DISEASE MODEL; DRUG EFFECTS; MALE; MOUSE; SEIZURES; SYNAPTIC TRANSMISSION; SYNTHESIS; TOXICITY TESTING;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; GABA AGENTS; MALE; MICE; SEIZURES; SYNAPTIC TRANSMISSION; TOXICITY TESTS; TRIAZOLES;

EID: 84906672894     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190811279     Document Type: Article

References (36)

1. Savage, N. Epidemiology: The complexities of epilepsy. Nature 2014, 511, S2-S3.
2. Berg, A.T.; Jallon, P.; Preux, P.M. The epidemiology of seizure disorders in infancy and childhood: Definitions and classifications. Handb. Clin. Neurol. 2013, 111, 391-398.
3. Heja, L. Astrocytic target mechanisms in epilepsy. Curr. Med. Chem. 2014, 21, 755-763.
4. Kaminski, R.M.; Rogawski, M.A.; Klitgaard, H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics 2014, 11, 385-400.
5. Meldrum, B.S.; Rogawski, M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4, 18-61.
6. Mantegazza, M.; Curia, G.; Biagini, G.; Ragsdale, D.S.; Avioli, M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010, 9, 413-424.
7. Lipkind, G.M.; Fozzard, H.A. Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol. Pharmacol. 2010, 78, 631-638.
8. Malawska, B. Application of pharmacophore models for the design and synthesis of new anticonvulsant drugs. Mini Rev. Med. Chem. 2003, 3, 341-348.
9. Pandeya, S.N.; Yogeeswari, P.; Stables, J.P. Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazones. Eur. J. Med. Chem. 2000, 35, 879-886.
10. Yogeeswari, P.; Sriram, D.; Jit, L.R.J.S.; Kumar, S.S.; Stables, J.P. Anticonvulsant and neurotoxicity evaluation of some 6-chlorobenzothiazolyl-2- thiosemicarbazones. Eur. J. Med. Chem. 2002, 37, 231-236.
11. 2 subunit. Proc. Natl. Acad. Sci. USA 1994, 91, 4569-4573.
12. Łuszczki, J.J.; Plech, T.; Wujec, M. Effect of 4-(4-bromophenyl)-5-(3-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2012, 690, 99-106.
13. Łuszczki, J.J.; Plech, T.; Wujec, M. Influence of 5-(3-chlorophenyl)-4-(4-methylphenyl)-2, 4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of four classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Pharmacol. Rep. 2012, 64, 970-978.
14. Shalini, M.; Yogeeswari, P.; Sriram, D.; Stables, J.P. Cyclization of the semicarbazone template of aryl semicarbazones: Synthesis and anticonvulsant activity of 4,5-diphenyl-2H-1,2,4-triazol-3(4H)-one. Biomed. Pharmacother. 2009, 63, 187-193.
15. Siddiqui, N.; Ahsan, W. Triazole incorporated thiazoles as a new class of anticonvulsants: Design, synthesis and in vivo screening. Eur. J. Med. Chem. 2010, 45, 1536-1543.
16. Almasirad, A.; Tabatabai, S.A.; Faizi, M.; Kebriaeezadeh, A.; Mehrabi, N.; Dalvandi, A.; Shafiee, A. Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2-fluorophenoxy)phenyl]-1,3, 4-oxadiazoles and 1,2,4-triazoles. Bioorg. Med. Chem. Lett. 2004, 14, 6057-6059.
17. Akbarzadeh, T.; Tabatabai, S.A.; Khoshnoud, M.J.; Shafaghi, B.; Shafiee, A. Design and synthesis of 4H-3-(2-phenoxy)phenyl-1,2,4-triazole derivatives as benzodiazepine receptor agonists. Bioorg. Med. Chem. 2003, 11, 769-773.
18. Plech, T.; Wujec, M.; Siwek, A.; Kosikowska, U.; Malm, A. Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety. Eur. J. Med. Chem. 2011, 46, 241-248.
19. Almajan, G.L.; Barbuceanu, S.F.; Almajan, E.R.; Draghici, C.; Saramet, G. Synthesis, characterization and antibacterial activity of some triazole Mannich bases carrying diphenylsulfone moieties. Eur. J. Med. Chem. 2009, 44, 3083-3089.
20. Van de Waterbeemd, H.; Camenish, G.; Folkers, G.; Chretien, J.R.; Raevsky, O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding characteristics. J. Drug Target. 1998, 6, 151-165.
21. Palm, K.; Luthman, K.; Ungell, A.L.; Strandlund, G.; Artursson, P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 1996, 85, 32-39.
22. Zhao, Y.; Abraham, M.H.; Lee, J.; Hersey, A.; Luscombe, N.C.; Beck, G.; Sherborne, B.; Cooper, I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 2002, 19, 1446-1457.
23. Chebib, M.; Johnston, G.A.R. The ABC of GABA receptors: A brief review. Clin. Exp. Pharmacol. Physiol. 1999, 26, 937-940.
24. Czuczwar, S.J.; Patsalos, P.N. The new generation of GABA enhancers. CNS Drugs 2001, 15, 339-350.
25. Czapihski, P.; Blaszczyk, B.; Czuczwar, S.J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 3-14.
26. Plech, T.; Łuszczki, J.J.; Wujec, M.; Flieger, J.; Pizoh, M. Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles. Eur. J. Med. Chem. 2013, 60, 208-215.
27. Flieger, J.; Pizoh, M.; Plech, T.; Łuszczki, J.J. Analysis of new potential anticonvulsant compounds in mice brain tissue by SPE/HPLC/DAD. J. Chromatogr. B 2012, 909, 26-33.
28. A receptors. Pharmaceuticals 2010, 3, 3461-3477.
29. Wafford, K.A.; Bain, C.J.; Quirk, K.; McKernan, R.M.; Wingrove, P.B.; Whiting, P.J.; Kemp, J.A. A novel allosteric modulatory site on the GABAA receptor beta subunit. Neuron 1994, 12, 775-782.
30. Molinspiration Property Calculator. Available online: http://www.molinspiration.com/cgi-bin/properties (accessed on 15 March 2014).
31. Plech, T.; Wujec, M.; Majewska, M.; Kosikowska, U.; Malm, A. Microbiologically active Mannich bases derived from 1,2,4-triazoles. The effect of C-5 substituent on antibacterial activity. Med. Chem. Res. 2013, 22, 2531-2537.
32. Plech, T.; Wujec, M.; Kaproh, B.; Kosikowska, U.; Malm, A. Synthesis and antibacterial activity of some novel N2-hydroxymethyl and N2-aminomethyl derivatives of 4-aryl-5-(3-chlorophenyl)-2, 4-dihydro-3H-1,2,4-triazole-3- thione. Heteroat. Chem. 2011, 22, 737-743.
33. Litchfield, J.T.; Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113.
34. Boissier, J.R.; Tardy, J.; Diverres, J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: Le test de la cheminée. Med. Exp. 1960, 3, 81-84.
35. Löscher, W.; Nolting, B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs IV. Protective indices. Epilepsy Res. 1991, 9, 1-10.
36. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.